Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

European Innovation Council · Running

NuCapCure Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

Coordinator
Universitetet I Oslo, Norway
Runs
1 February 2024 to 31 July 2028
Status
Running
EU funding
€6.0m
Total cost
€6.0m
Partners
8 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101130209

What the project is doing

In the project's own words, from its summary on CORDIS.

Deep-lying cancers, such as glioblastoma multiforme (GBM) brain cancer, are very difficult to access and incurable by the current standards of care. The fluorescence of photosensitive molecules (PSs) can precisely guide surgical resection of GBM. Nevertheless, photomedical treatments like photodynamic therapy (PDT) show limited efficacies due to the low penetration of light into tissue. Proton radiotherapy can reach deep-lying disease through therapeutic energy deposition in a spatially confined region called Bragg peak.

Current neutron-based therapies, like Boron Neutron Capture Therapy (BNCT), have sufficient penetration depth but lack cancer specificity. In NuCapCure, we propose to 'hijack' intracellular biosynthetic pathways and use them to produce custom-made drugs that will facilitate two genuinely new cancer treatments: i) ""NuCapCure Proton"", combining proton radiotherapy, protondynamic therapy through PS proton activation, and proton capture therapy (BPCT) through three produced alpha particles

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I OsloOsloNorwayCoordinator
Centrum Vyzkumu Rez SroHusinec-RezCzechiaParticipant
Univerzita KarlovaPraha 1CzechiaParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
National Center for Scientific Research ""demokritos""""Agia ParaskeviGreeceParticipant
Galchimia SATouro A CorunaSpainParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Oslo Universitetssykehus HfOsloNorwayThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI